Skip to main content
Premium Trial:

Request an Annual Quote

Brazilian Health Regulatory Agency Approves Premaitha's Noninvasive Prenatal Test as IVD

NEW YORK (GenomeWeb) – Premaitha Health said today that the Brazilian Health Regulatory Agency (ANVISA) has approved its Iona noninvasive prenatal test as an in vitro diagnostic.

Last September, the agency had already granted the Iona test Brazilian Good Manufacturing Practice (B-GMP) approval, a requirement to register it with ANVISA.

Premaitha said it is now seeking commercial partners in Brazil to make the test available in the country.

"Commercializing the Iona test in this significant South American market is another key step in Premaitha's diversification and de-risking strategy," said Premaitha CEO Stephen Little in a statement. "Whilst the territory will not be immediately revenue generating, with over 3 million births per annum, we anticipate Brazil will become a major market for Premaitha and that it will in due course provide a springboard to other South and Central America regions."

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.